nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—SLCO1A2—Levothyroxine—hypothyroidism	0.119	0.16	CbGbCtD
Naloxone—SLCO1A2—Liothyronine—hypothyroidism	0.119	0.16	CbGbCtD
Naloxone—SLCO1A2—Liotrix—hypothyroidism	0.116	0.156	CbGbCtD
Naloxone—ALB—Liothyronine—hypothyroidism	0.0615	0.0824	CbGbCtD
Naloxone—ALB—Levothyroxine—hypothyroidism	0.0615	0.0824	CbGbCtD
Naloxone—ALB—Liotrix—hypothyroidism	0.0601	0.0804	CbGbCtD
Naloxone—CYP2C8—Levothyroxine—hypothyroidism	0.0476	0.0637	CbGbCtD
Naloxone—CYP2C8—Liotrix—hypothyroidism	0.0464	0.0622	CbGbCtD
Naloxone—ABCB1—Levothyroxine—hypothyroidism	0.0322	0.0431	CbGbCtD
Naloxone—ABCB1—Liothyronine—hypothyroidism	0.0322	0.0431	CbGbCtD
Naloxone—ABCB1—Liotrix—hypothyroidism	0.0314	0.0421	CbGbCtD
Naloxone—CYP3A4—Levothyroxine—hypothyroidism	0.0193	0.0258	CbGbCtD
Naloxone—CREB1—nerve—hypothyroidism	0.00612	0.0759	CbGeAlD
Naloxone—Abdominal cramps—Levothyroxine—hypothyroidism	0.00539	0.0486	CcSEcCtD
Naloxone—Abdominal cramps—Dextrothyroxine—hypothyroidism	0.00539	0.0486	CcSEcCtD
Naloxone—TLR4—heart—hypothyroidism	0.00516	0.064	CbGeAlD
Naloxone—Abdominal cramps—Liotrix—hypothyroidism	0.00396	0.0357	CcSEcCtD
Naloxone—TLR4—adrenal gland—hypothyroidism	0.00385	0.0478	CbGeAlD
Naloxone—TLR4—blood—hypothyroidism	0.00385	0.0478	CbGeAlD
Naloxone—TLR4—thyroid gland—hypothyroidism	0.00372	0.0461	CbGeAlD
Naloxone—TLR4—female gonad—hypothyroidism	0.00359	0.0445	CbGeAlD
Naloxone—Coma—Dextrothyroxine—hypothyroidism	0.00332	0.03	CcSEcCtD
Naloxone—Coma—Levothyroxine—hypothyroidism	0.00332	0.03	CcSEcCtD
Naloxone—OPRM1—nerve—hypothyroidism	0.0033	0.0409	CbGeAlD
Naloxone—TLR4—testis—hypothyroidism	0.00318	0.0395	CbGeAlD
Naloxone—Hyperkinesia—Dextrothyroxine—hypothyroidism	0.00317	0.0286	CcSEcCtD
Naloxone—Hyperkinesia—Levothyroxine—hypothyroidism	0.00317	0.0286	CcSEcCtD
Naloxone—TLR4—liver—hypothyroidism	0.00301	0.0374	CbGeAlD
Naloxone—TLR4—cerebellum—hypothyroidism	0.00294	0.0365	CbGeAlD
Naloxone—Hypertension—Liothyronine—hypothyroidism	0.0028	0.0252	CcSEcCtD
Naloxone—Tachycardia—Liothyronine—hypothyroidism	0.00258	0.0232	CcSEcCtD
Naloxone—Irritability—Levothyroxine—hypothyroidism	0.00252	0.0227	CcSEcCtD
Naloxone—Irritability—Dextrothyroxine—hypothyroidism	0.00252	0.0227	CcSEcCtD
Naloxone—Cardiac arrest—Levothyroxine—hypothyroidism	0.00251	0.0226	CcSEcCtD
Naloxone—Cardiac arrest—Dextrothyroxine—hypothyroidism	0.00251	0.0226	CcSEcCtD
Naloxone—Coma—Liotrix—hypothyroidism	0.00244	0.022	CcSEcCtD
Naloxone—Hyperkinesia—Liotrix—hypothyroidism	0.00233	0.021	CcSEcCtD
Naloxone—CREB1—heart—hypothyroidism	0.00227	0.0282	CbGeAlD
Naloxone—CREB1—cardiovascular system—hypothyroidism	0.00214	0.0266	CbGeAlD
Naloxone—Body temperature increased—Liothyronine—hypothyroidism	0.00209	0.0188	CcSEcCtD
Naloxone—Sweating—Dextrothyroxine—hypothyroidism	0.00195	0.0176	CcSEcCtD
Naloxone—Sweating—Levothyroxine—hypothyroidism	0.00195	0.0176	CcSEcCtD
Naloxone—CYP3A4—urine—hypothyroidism	0.00195	0.0242	CbGeAlD
Naloxone—CREB1—gonad—hypothyroidism	0.00194	0.0241	CbGeAlD
Naloxone—CREB1—pituitary gland—hypothyroidism	0.0019	0.0235	CbGeAlD
Naloxone—Irritability—Liotrix—hypothyroidism	0.00185	0.0167	CcSEcCtD
Naloxone—Cardiac arrest—Liotrix—hypothyroidism	0.00185	0.0166	CcSEcCtD
Naloxone—Flushing—Levothyroxine—hypothyroidism	0.0017	0.0153	CcSEcCtD
Naloxone—Flushing—Dextrothyroxine—hypothyroidism	0.0017	0.0153	CcSEcCtD
Naloxone—CREB1—adrenal gland—hypothyroidism	0.00169	0.021	CbGeAlD
Naloxone—CREB1—blood—hypothyroidism	0.00169	0.021	CbGeAlD
Naloxone—CREB1—thyroid gland—hypothyroidism	0.00164	0.0203	CbGeAlD
Naloxone—CREB1—female gonad—hypothyroidism	0.00158	0.0196	CbGeAlD
Naloxone—Tension—Dextrothyroxine—hypothyroidism	0.00156	0.0141	CcSEcCtD
Naloxone—Tension—Levothyroxine—hypothyroidism	0.00156	0.0141	CcSEcCtD
Naloxone—Nervousness—Levothyroxine—hypothyroidism	0.00154	0.0139	CcSEcCtD
Naloxone—Nervousness—Dextrothyroxine—hypothyroidism	0.00154	0.0139	CcSEcCtD
Naloxone—Tremor—Levothyroxine—hypothyroidism	0.00149	0.0134	CcSEcCtD
Naloxone—Tremor—Dextrothyroxine—hypothyroidism	0.00149	0.0134	CcSEcCtD
Naloxone—Agitation—Dextrothyroxine—hypothyroidism	0.00146	0.0132	CcSEcCtD
Naloxone—Agitation—Levothyroxine—hypothyroidism	0.00146	0.0132	CcSEcCtD
Naloxone—Sweating—Liotrix—hypothyroidism	0.00143	0.0129	CcSEcCtD
Naloxone—CREB1—testis—hypothyroidism	0.0014	0.0174	CbGeAlD
Naloxone—Convulsion—Dextrothyroxine—hypothyroidism	0.00138	0.0124	CcSEcCtD
Naloxone—Convulsion—Levothyroxine—hypothyroidism	0.00138	0.0124	CcSEcCtD
Naloxone—CREB1—liver—hypothyroidism	0.00133	0.0164	CbGeAlD
Naloxone—CREB1—cerebellum—hypothyroidism	0.00129	0.0161	CbGeAlD
Naloxone—Tachycardia—Dextrothyroxine—hypothyroidism	0.00127	0.0114	CcSEcCtD
Naloxone—Tachycardia—Levothyroxine—hypothyroidism	0.00127	0.0114	CcSEcCtD
Naloxone—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00125	0.0113	CcSEcCtD
Naloxone—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00125	0.0113	CcSEcCtD
Naloxone—Flushing—Liotrix—hypothyroidism	0.00125	0.0112	CcSEcCtD
Naloxone—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00116	0.0104	CcSEcCtD
Naloxone—Dyspnoea—Levothyroxine—hypothyroidism	0.00116	0.0104	CcSEcCtD
Naloxone—Tension—Liotrix—hypothyroidism	0.00115	0.0103	CcSEcCtD
Naloxone—Nervousness—Liotrix—hypothyroidism	0.00114	0.0102	CcSEcCtD
Naloxone—Tremor—Liotrix—hypothyroidism	0.0011	0.00988	CcSEcCtD
Naloxone—Agitation—Liotrix—hypothyroidism	0.00107	0.00969	CcSEcCtD
Naloxone—ALB—heart—hypothyroidism	0.00105	0.013	CbGeAlD
Naloxone—Body temperature increased—Levothyroxine—hypothyroidism	0.00103	0.00925	CcSEcCtD
Naloxone—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00103	0.00925	CcSEcCtD
Naloxone—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00103	0.00925	CcSEcCtD
Naloxone—Abdominal pain—Levothyroxine—hypothyroidism	0.00103	0.00925	CcSEcCtD
Naloxone—Convulsion—Liotrix—hypothyroidism	0.00101	0.00913	CcSEcCtD
Naloxone—Hypertension—Liotrix—hypothyroidism	0.00101	0.0091	CcSEcCtD
Naloxone—OPRK1—cerebellum—hypothyroidism	0.000981	0.0122	CbGeAlD
Naloxone—Tachycardia—Liotrix—hypothyroidism	0.000932	0.0084	CcSEcCtD
Naloxone—Asthenia—Dextrothyroxine—hypothyroidism	0.000931	0.00839	CcSEcCtD
Naloxone—Asthenia—Levothyroxine—hypothyroidism	0.000931	0.00839	CcSEcCtD
Naloxone—Hyperhidrosis—Liotrix—hypothyroidism	0.000923	0.00832	CcSEcCtD
Naloxone—OPRM1—blood—hypothyroidism	0.000913	0.0113	CbGeAlD
Naloxone—ESR1—heart—hypothyroidism	0.000894	0.0111	CbGeAlD
Naloxone—Diarrhoea—Levothyroxine—hypothyroidism	0.000888	0.008	CcSEcCtD
Naloxone—Diarrhoea—Dextrothyroxine—hypothyroidism	0.000888	0.008	CcSEcCtD
Naloxone—Paraesthesia—Liotrix—hypothyroidism	0.000857	0.00773	CcSEcCtD
Naloxone—Dyspnoea—Liotrix—hypothyroidism	0.000851	0.00767	CcSEcCtD
Naloxone—ESR1—cardiovascular system—hypothyroidism	0.000843	0.0105	CbGeAlD
Naloxone—Vomiting—Levothyroxine—hypothyroidism	0.000825	0.00744	CcSEcCtD
Naloxone—Vomiting—Dextrothyroxine—hypothyroidism	0.000825	0.00744	CcSEcCtD
Naloxone—ALB—adrenal gland—hypothyroidism	0.000782	0.0097	CbGeAlD
Naloxone—Nausea—Dextrothyroxine—hypothyroidism	0.000771	0.00695	CcSEcCtD
Naloxone—Nausea—Levothyroxine—hypothyroidism	0.000771	0.00695	CcSEcCtD
Naloxone—ESR1—gonad—hypothyroidism	0.000765	0.0095	CbGeAlD
Naloxone—OPRM1—testis—hypothyroidism	0.000756	0.00938	CbGeAlD
Naloxone—Body temperature increased—Liotrix—hypothyroidism	0.000755	0.0068	CcSEcCtD
Naloxone—Abdominal pain—Liotrix—hypothyroidism	0.000755	0.0068	CcSEcCtD
Naloxone—ESR1—pituitary gland—hypothyroidism	0.000747	0.00927	CbGeAlD
Naloxone—Asthenia—Liotrix—hypothyroidism	0.000685	0.00617	CcSEcCtD
Naloxone—ESR1—adrenal gland—hypothyroidism	0.000667	0.00828	CbGeAlD
Naloxone—ESR1—blood—hypothyroidism	0.000667	0.00828	CbGeAlD
Naloxone—Diarrhoea—Liotrix—hypothyroidism	0.000653	0.00589	CcSEcCtD
Naloxone—SLCO1A2—testis—hypothyroidism	0.00065	0.00807	CbGeAlD
Naloxone—ALB—testis—hypothyroidism	0.000647	0.00803	CbGeAlD
Naloxone—ESR1—thyroid gland—hypothyroidism	0.000644	0.00799	CbGeAlD
Naloxone—ESR1—female gonad—hypothyroidism	0.000622	0.00772	CbGeAlD
Naloxone—CYP2C8—pituitary gland—hypothyroidism	0.000615	0.00763	CbGeAlD
Naloxone—SLCO1A2—liver—hypothyroidism	0.000615	0.00763	CbGeAlD
Naloxone—ALB—liver—hypothyroidism	0.000611	0.00759	CbGeAlD
Naloxone—Vomiting—Liotrix—hypothyroidism	0.000607	0.00547	CcSEcCtD
Naloxone—SLCO1A2—cerebellum—hypothyroidism	0.000601	0.00746	CbGeAlD
Naloxone—Nausea—Liotrix—hypothyroidism	0.000567	0.00511	CcSEcCtD
Naloxone—ESR1—testis—hypothyroidism	0.000552	0.00685	CbGeAlD
Naloxone—CYP2C8—blood—hypothyroidism	0.000549	0.00682	CbGeAlD
Naloxone—ESR1—liver—hypothyroidism	0.000522	0.00647	CbGeAlD
Naloxone—ESR1—cerebellum—hypothyroidism	0.00051	0.00632	CbGeAlD
Naloxone—CYP2C8—testis—hypothyroidism	0.000454	0.00564	CbGeAlD
Naloxone—CYP2C8—liver—hypothyroidism	0.00043	0.00533	CbGeAlD
Naloxone—CYP3A4—blood—hypothyroidism	0.000372	0.00462	CbGeAlD
Naloxone—ABCB1—adrenal cortex—hypothyroidism	0.000365	0.00453	CbGeAlD
Naloxone—ABCB1—heart—hypothyroidism	0.000353	0.00438	CbGeAlD
Naloxone—ABCB1—cardiovascular system—hypothyroidism	0.000333	0.00413	CbGeAlD
Naloxone—OPRK1—Peptide ligand-binding receptors—TRH—hypothyroidism	0.000309	0.00501	CbGpPWpGaD
Naloxone—SLCO1A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000308	0.00499	CbGpPWpGaD
Naloxone—ABCB1—gonad—hypothyroidism	0.000302	0.00375	CbGeAlD
Naloxone—ABCB1—pituitary gland—hypothyroidism	0.000295	0.00366	CbGeAlD
Naloxone—CYP3A4—liver—hypothyroidism	0.000291	0.00361	CbGeAlD
Naloxone—TLR4—Immune System—CLTC—hypothyroidism	0.000281	0.00455	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—NEFL—hypothyroidism	0.00028	0.00453	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—CLTC—hypothyroidism	0.000267	0.00432	CbGpPWpGaD
Naloxone—ALB—Transport of vitamins, nucleosides, and related molecules—AVP—hypothyroidism	0.000266	0.00431	CbGpPWpGaD
Naloxone—ESR1—Plasma membrane estrogen receptor signaling—IGF1—hypothyroidism	0.000265	0.00429	CbGpPWpGaD
Naloxone—ABCB1—adrenal gland—hypothyroidism	0.000263	0.00327	CbGeAlD
Naloxone—ABCB1—blood—hypothyroidism	0.000263	0.00327	CbGeAlD
Naloxone—OPRM1—Peptide ligand-binding receptors—TRH—hypothyroidism	0.000261	0.00423	CbGpPWpGaD
Naloxone—OPRM1—TCR Signaling Pathway—VAV3—hypothyroidism	0.000259	0.00419	CbGpPWpGaD
Naloxone—ABCB1—thyroid gland—hypothyroidism	0.000254	0.00316	CbGeAlD
Naloxone—CREB1—Signaling by ERBB4—PRL—hypothyroidism	0.000249	0.00403	CbGpPWpGaD
Naloxone—ABCB1—female gonad—hypothyroidism	0.000246	0.00305	CbGeAlD
Naloxone—CREB1—Opioid Signalling—POMC—hypothyroidism	0.000244	0.00395	CbGpPWpGaD
Naloxone—CREB1—Glucocorticoid receptor regulatory network—POMC—hypothyroidism	0.000242	0.00392	CbGpPWpGaD
Naloxone—CREB1—BDNF signaling pathway—VAV3—hypothyroidism	0.000241	0.0039	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000236	0.00383	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—THRA—hypothyroidism	0.000235	0.0038	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—VAV3—hypothyroidism	0.000227	0.00368	CbGpPWpGaD
Naloxone—CREB1—Corticotropin-releasing hormone—POMC—hypothyroidism	0.000221	0.00357	CbGpPWpGaD
Naloxone—CREB1—EGF/EGFR Signaling Pathway—VAV3—hypothyroidism	0.000219	0.00355	CbGpPWpGaD
Naloxone—ABCB1—testis—hypothyroidism	0.000218	0.0027	CbGeAlD
Naloxone—CREB1—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000217	0.00352	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—VAV3—hypothyroidism	0.000217	0.00351	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000211	0.00341	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000211	0.00341	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000207	0.00336	CbGpPWpGaD
Naloxone—ABCB1—liver—hypothyroidism	0.000206	0.00256	CbGeAlD
Naloxone—CREB1—DAP12 interactions—VAV3—hypothyroidism	0.000204	0.0033	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—VAV3—hypothyroidism	0.000204	0.0033	CbGpPWpGaD
Naloxone—ABCB1—cerebellum—hypothyroidism	0.000201	0.0025	CbGeAlD
Naloxone—CREB1—Developmental Biology—CLTC—hypothyroidism	0.00019	0.00308	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000189	0.00306	CbGpPWpGaD
Naloxone—OPRD1—Peptide ligand-binding receptors—AVP—hypothyroidism	0.000185	0.003	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000185	0.00299	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000185	0.00299	CbGpPWpGaD
Naloxone—ALB—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000182	0.00294	CbGpPWpGaD
Naloxone—OPRM1—Opioid Signalling—POMC—hypothyroidism	0.00018	0.00292	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—TRH—hypothyroidism	0.00018	0.00292	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—AVP—hypothyroidism	0.000178	0.00288	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—ZNF764—hypothyroidism	0.000175	0.00284	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000175	0.00284	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000168	0.00272	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—NKX2-5—hypothyroidism	0.000167	0.00271	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—PRL—hypothyroidism	0.000163	0.00264	CbGpPWpGaD
Naloxone—OPRK1—Peptide ligand-binding receptors—AVP—hypothyroidism	0.000162	0.00263	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CLTC—hypothyroidism	0.000162	0.00262	CbGpPWpGaD
Naloxone—CREB1—Adipogenesis—IGF1—hypothyroidism	0.000161	0.0026	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—TSHB—hypothyroidism	0.00016	0.0026	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—TSHR—hypothyroidism	0.00016	0.0026	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—TRH—hypothyroidism	0.000158	0.00256	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000157	0.00254	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000156	0.00253	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000156	0.00253	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—THRB—hypothyroidism	0.000151	0.00245	CbGpPWpGaD
Naloxone—ALB—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000151	0.00244	CbGpPWpGaD
Naloxone—SLCO1A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000149	0.00241	CbGpPWpGaD
Naloxone—TLR4—Immune System—PRL—hypothyroidism	0.000143	0.00232	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—TSHB—hypothyroidism	0.000141	0.00228	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—TSHR—hypothyroidism	0.000141	0.00228	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—VAV3—hypothyroidism	0.000139	0.00225	CbGpPWpGaD
Naloxone—OPRM1—Peptide ligand-binding receptors—AVP—hypothyroidism	0.000137	0.00222	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—TRH—hypothyroidism	0.000133	0.00216	CbGpPWpGaD
Naloxone—TLR4—Immune System—VAV3—hypothyroidism	0.000132	0.00214	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—IYD—hypothyroidism	0.000128	0.00207	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—VAV3—hypothyroidism	0.000126	0.00204	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000124	0.00201	CbGpPWpGaD
Naloxone—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000123	0.002	CbGpPWpGaD
Naloxone—OPRD1—Peptide ligand-binding receptors—POMC—hypothyroidism	0.000123	0.00199	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—TSHB—hypothyroidism	0.000119	0.00193	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—TSHR—hypothyroidism	0.000119	0.00193	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000118	0.00191	CbGpPWpGaD
Naloxone—SLCO1A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000117	0.00189	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—THRA—hypothyroidism	0.000113	0.00183	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000109	0.00176	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ATP5O—hypothyroidism	0.000109	0.00176	CbGpPWpGaD
Naloxone—OPRK1—Peptide ligand-binding receptors—POMC—hypothyroidism	0.000108	0.00175	CbGpPWpGaD
Naloxone—OPRD1—G alpha (i) signalling events—POMC—hypothyroidism	0.000104	0.00168	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—TPO—hypothyroidism	0.000102	0.00165	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—TRH—hypothyroidism	0.000102	0.00165	CbGpPWpGaD
Naloxone—CYP2C8—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.0001	0.00162	CbGpPWpGaD
Naloxone—CREB1—Immune System—CLTC—hypothyroidism	9.8e-05	0.00159	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—AVP—hypothyroidism	9.46e-05	0.00153	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	9.46e-05	0.00153	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—IGF1—hypothyroidism	9.38e-05	0.00152	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—TRH—hypothyroidism	9.27e-05	0.0015	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—TRH—hypothyroidism	9.24e-05	0.0015	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	9.23e-05	0.00149	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	9.2e-05	0.00149	CbGpPWpGaD
Naloxone—OPRM1—Peptide ligand-binding receptors—POMC—hypothyroidism	9.12e-05	0.00148	CbGpPWpGaD
Naloxone—OPRK1—G alpha (i) signalling events—POMC—hypothyroidism	9.1e-05	0.00147	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—TSHB—hypothyroidism	9.07e-05	0.00147	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—TSHR—hypothyroidism	9.07e-05	0.00147	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—VAV3—hypothyroidism	8.98e-05	0.00145	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—hypothyroidism	8.94e-05	0.00145	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—TRH—hypothyroidism	8.92e-05	0.00144	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—AVP—hypothyroidism	8.29e-05	0.00134	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—TSHR—hypothyroidism	8.26e-05	0.00134	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—TSHB—hypothyroidism	8.26e-05	0.00134	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	8.25e-05	0.00134	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—TSHB—hypothyroidism	8.24e-05	0.00133	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—TSHR—hypothyroidism	8.24e-05	0.00133	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—TRH—hypothyroidism	8.1e-05	0.00131	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	8.09e-05	0.00131	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—NKX2-5—hypothyroidism	8.05e-05	0.0013	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—TSHB—hypothyroidism	7.95e-05	0.00129	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—TSHR—hypothyroidism	7.95e-05	0.00129	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—VAV3—hypothyroidism	7.93e-05	0.00128	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	7.74e-05	0.00125	CbGpPWpGaD
Naloxone—OPRM1—G alpha (i) signalling events—POMC—hypothyroidism	7.69e-05	0.00125	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	7.65e-05	0.00124	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	7.55e-05	0.00122	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—TRH—hypothyroidism	7.54e-05	0.00122	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—THRB—hypothyroidism	7.28e-05	0.00118	CbGpPWpGaD
Naloxone—ALB—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	7.26e-05	0.00118	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	7.24e-05	0.00117	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—TSHB—hypothyroidism	7.22e-05	0.00117	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—TSHR—hypothyroidism	7.22e-05	0.00117	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—AVP—hypothyroidism	7.01e-05	0.00114	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—TRH—hypothyroidism	6.85e-05	0.00111	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	6.76e-05	0.00109	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—TSHB—hypothyroidism	6.72e-05	0.00109	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—TSHR—hypothyroidism	6.72e-05	0.00109	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	6.7e-05	0.00109	CbGpPWpGaD
Naloxone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	6.63e-05	0.00107	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CLTC—hypothyroidism	6.34e-05	0.00103	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CLTC—hypothyroidism	6.32e-05	0.00102	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—POMC—hypothyroidism	6.29e-05	0.00102	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—IYD—hypothyroidism	6.27e-05	0.00102	CbGpPWpGaD
Naloxone—ALB—Metabolism—IYD—hypothyroidism	6.24e-05	0.00101	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.12e-05	0.00099	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—TSHB—hypothyroidism	6.1e-05	0.000988	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—TSHR—hypothyroidism	6.1e-05	0.000988	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—AVP—hypothyroidism	5.95e-05	0.000963	CbGpPWpGaD
Naloxone—ALB—SLC-mediated transmembrane transport—AVP—hypothyroidism	5.72e-05	0.000926	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—VAV3—hypothyroidism	5.55e-05	0.000898	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CLTC—hypothyroidism	5.54e-05	0.000897	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—POMC—hypothyroidism	5.51e-05	0.000892	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TRH—hypothyroidism	5.48e-05	0.000887	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—IYD—hypothyroidism	5.47e-05	0.000885	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TRH—hypothyroidism	5.46e-05	0.000884	CbGpPWpGaD
Naloxone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	5.37e-05	0.00087	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AVP—hypothyroidism	5.34e-05	0.000866	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ATP5O—hypothyroidism	5.33e-05	0.000864	CbGpPWpGaD
Naloxone—CYP2C8—Biological oxidations—POMC—hypothyroidism	5.32e-05	0.000861	CbGpPWpGaD
Naloxone—ALB—Metabolism—ATP5O—hypothyroidism	5.3e-05	0.000859	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SH2B3—hypothyroidism	5.07e-05	0.000822	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—VAV3—hypothyroidism	5.05e-05	0.000818	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—VAV3—hypothyroidism	5.04e-05	0.000816	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TPO—hypothyroidism	5.01e-05	0.000812	CbGpPWpGaD
Naloxone—CREB1—Immune System—PRL—hypothyroidism	4.99e-05	0.000808	CbGpPWpGaD
Naloxone—ALB—Metabolism—TPO—hypothyroidism	4.99e-05	0.000807	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TSHB—hypothyroidism	4.88e-05	0.00079	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TSHR—hypothyroidism	4.88e-05	0.00079	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AVP—hypothyroidism	4.87e-05	0.000788	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TSHB—hypothyroidism	4.86e-05	0.000788	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TSHR—hypothyroidism	4.86e-05	0.000788	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—VAV3—hypothyroidism	4.86e-05	0.000788	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AVP—hypothyroidism	4.85e-05	0.000786	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TRH—hypothyroidism	4.79e-05	0.000775	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—TSHB—hypothyroidism	4.72e-05	0.000765	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AVP—hypothyroidism	4.69e-05	0.000759	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CLTC—hypothyroidism	4.68e-05	0.000758	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—POMC—hypothyroidism	4.66e-05	0.000754	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ATP5O—hypothyroidism	4.65e-05	0.000752	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	4.65e-05	0.000752	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	4.62e-05	0.000748	CbGpPWpGaD
Naloxone—CREB1—Immune System—VAV3—hypothyroidism	4.62e-05	0.000748	CbGpPWpGaD
Naloxone—CREB1—Disease—PRL—hypothyroidism	4.61e-05	0.000746	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—VAV3—hypothyroidism	4.42e-05	0.000715	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TPO—hypothyroidism	4.37e-05	0.000707	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SH2B3—hypothyroidism	4.35e-05	0.000704	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SH2B3—hypothyroidism	4.34e-05	0.000702	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TSHB—hypothyroidism	4.27e-05	0.000691	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TSHR—hypothyroidism	4.27e-05	0.000691	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AVP—hypothyroidism	4.26e-05	0.000689	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3C2A—hypothyroidism	4.21e-05	0.000682	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	4.16e-05	0.000674	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	4.16e-05	0.000673	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CLTC—hypothyroidism	4.15e-05	0.000672	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—VAV3—hypothyroidism	4.11e-05	0.000666	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	4.1e-05	0.000664	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TRH—hypothyroidism	4.04e-05	0.000655	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AVP—hypothyroidism	3.96e-05	0.000641	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SH2B3—hypothyroidism	3.8e-05	0.000616	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—VAV3—hypothyroidism	3.73e-05	0.000605	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	3.69e-05	0.000597	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TSHB—hypothyroidism	3.61e-05	0.000584	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TSHR—hypothyroidism	3.61e-05	0.000584	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AVP—hypothyroidism	3.6e-05	0.000582	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TRH—hypothyroidism	3.59e-05	0.000581	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—POMC—hypothyroidism	3.55e-05	0.000575	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—SLC5A5—hypothyroidism	3.54e-05	0.000573	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VAV3—hypothyroidism	3.48e-05	0.000564	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—IYD—hypothyroidism	3.37e-05	0.000545	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—POMC—hypothyroidism	3.24e-05	0.000524	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	3.23e-05	0.000524	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PRL—hypothyroidism	3.23e-05	0.000523	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—POMC—hypothyroidism	3.23e-05	0.000522	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PRL—hypothyroidism	3.22e-05	0.000521	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SH2B3—hypothyroidism	3.21e-05	0.00052	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TSHB—hypothyroidism	3.2e-05	0.000518	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TSHR—hypothyroidism	3.2e-05	0.000518	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—POMC—hypothyroidism	3.11e-05	0.000504	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VAV3—hypothyroidism	2.99e-05	0.000483	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VAV3—hypothyroidism	2.98e-05	0.000482	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—AVP—hypothyroidism	2.9e-05	0.00047	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AVP—hypothyroidism	2.88e-05	0.000466	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AVP—hypothyroidism	2.87e-05	0.000464	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ATP5O—hypothyroidism	2.86e-05	0.000464	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—POMC—hypothyroidism	2.85e-05	0.000462	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SH2B3—hypothyroidism	2.85e-05	0.000461	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—POMC—hypothyroidism	2.83e-05	0.000458	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PRL—hypothyroidism	2.82e-05	0.000457	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TPO—hypothyroidism	2.69e-05	0.000436	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—POMC—hypothyroidism	2.63e-05	0.000426	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VAV3—hypothyroidism	2.61e-05	0.000423	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	2.55e-05	0.000412	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AVP—hypothyroidism	2.51e-05	0.000407	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—POMC—hypothyroidism	2.39e-05	0.000387	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PRL—hypothyroidism	2.38e-05	0.000386	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TSHB—hypothyroidism	2.32e-05	0.000376	CbGpPWpGaD
Naloxone—ALB—Metabolism—TSHB—hypothyroidism	2.31e-05	0.000374	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VAV3—hypothyroidism	2.21e-05	0.000357	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IGF1—hypothyroidism	2.15e-05	0.000347	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AVP—hypothyroidism	2.12e-05	0.000344	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PRL—hypothyroidism	2.11e-05	0.000342	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	2.07e-05	0.000335	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3C2A—hypothyroidism	2.06e-05	0.000333	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	2.04e-05	0.000331	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	2.03e-05	0.000329	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TSHB—hypothyroidism	2.02e-05	0.000328	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VAV3—hypothyroidism	1.96e-05	0.000317	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—POMC—hypothyroidism	1.91e-05	0.00031	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—POMC—hypothyroidism	1.91e-05	0.000309	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AVP—hypothyroidism	1.88e-05	0.000305	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—POMC—hypothyroidism	1.85e-05	0.0003	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF1—hypothyroidism	1.84e-05	0.000298	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1—hypothyroidism	1.83e-05	0.000297	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3C2A—hypothyroidism	1.8e-05	0.000292	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SLC5A5—hypothyroidism	1.74e-05	0.000281	CbGpPWpGaD
Naloxone—ALB—Metabolism—SLC5A5—hypothyroidism	1.73e-05	0.00028	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—POMC—hypothyroidism	1.67e-05	0.000271	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1—hypothyroidism	1.61e-05	0.00026	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC5A5—hypothyroidism	1.51e-05	0.000245	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—POMC—hypothyroidism	1.41e-05	0.000229	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1—hypothyroidism	1.36e-05	0.00022	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—POMC—hypothyroidism	1.25e-05	0.000203	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TSHB—hypothyroidism	1.25e-05	0.000202	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—hypothyroidism	1.2e-05	0.000195	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	1.11e-05	0.00018	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—hypothyroidism	9.33e-06	0.000151	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—POMC—hypothyroidism	9.09e-06	0.000147	CbGpPWpGaD
Naloxone—ALB—Metabolism—POMC—hypothyroidism	9.04e-06	0.000146	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—POMC—hypothyroidism	7.92e-06	0.000128	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—POMC—hypothyroidism	4.88e-06	7.9e-05	CbGpPWpGaD
